背景： 在已發展中國家，如歐美國家，肥胖人口比例幾乎是逐年增加。根據世界衛生組織統計，美國在2000年的過重、肥胖人數佔總成人口數的三分之二。因此，在歐美國家中肥胖是一個很嚴重的公共健康問題。肥胖影響癌症的機制至今還不是很清楚瞭解，但多數研究則發現與肥胖相關荷爾蒙、蛋白質有所關連。流行病理學的研究，也支持與肥胖相關的分子是影響癌症的研究結果。但是，肥胖與癌症的預後因子、病人存活率的相關研究卻非常的少見。在台灣，肥胖問題雖然沒歐美國家嚴重，但流行率卻也逐年增加中，在過不久，肥胖也將是一個很嚴重的公共衛生問題。然而，台灣探討肥胖與癌症關連性的研究少之又少，因此，肥胖與癌症的研究則需去建立。
方法： 從台灣大學附屬醫院中所收集到的病例總共237個，其中肺癌病例為114個，收案時間1995-1997。卵巢癌病例為123個，收案時間1991-1997。身體質量指數為肥胖測量指標。本研究中的統計方法包含卡方分析、Kaplan-Meier方法和log-rank分析。
結果： 結果發現，卵巢癌病人中，肥胖不僅僅與晚期癌症有著關連性存在，存活分析的結果中，過重、肥胖病人的存活率明顯較差(P<0.05)。相較起來，肺癌病人之身體質量指數與預後因子和存活率間沒有任何顯著結果發現 (P>0.05)。合併身體質量指數與癌症分期，過重、肥胖且晚期的卵巢癌病人與正常身體質量指數且早期病人相較起來，不僅僅存活率較差，預後狀態也明顯較差。
結論： 此研究發現，卵巢癌病人中，身體質量指數與期別、病人存活率有所關連。合併身體質量指數與癌症分期，過重、肥胖且晚期卵巢癌病人不僅僅有最低存活率，預後也最差。相較起來，肺癌病人之身體質量指數與預後因子及存活率間沒有發現任何關連性。因此，這是台灣第一篇發現支持肥胖與荷爾蒙相關癌症有所關連的研究。

Background: Obesity which might be considered as the malnutrition of the developed world, has reached endemic proportions and its prevalence continues to increase, particularly in the affluent countries of Europe and the United states. By the year 2000, nearly two-thirds of adults in the United States and an increasing percentage of the population worldwide are overweight or obese as defined by the World Health Organization. Adiposity has strong effects on metabolic factors that may subsequently affect cancer risk; in particular, on circulating levels of peptide and steroid hormones and their binding factors. However, the association of body mass index (BMI) with prognostic factors and patient survival remains largely unknown and needs to be established.
Methods: Clinicopathologic data of 114 lung cancer patients between 1995 and 1997 and 123 ovarian cancer patients between 1991 and 1999 who underwent initial surgical resection for primary tumor at National Taiwan University Hospital, Taipei, Taiwan were retrospectively collected. The BMI was used as measures of obesity and was analyzed as prognosticator of recurrence/metastasis and patients survival.
Results: BMI was found to be associated with stage of ovarian cancer (P<0.05), but not associated with prognostic factors of lung cancer. Moreover, BMI was found to be associated with poor prognostic status of ovarian cancer (P<0.05) but not associated with outcome of lung cancer. Combination of BMI and stage, overweight/obese patients of ovarian cancer at advanced stage had even much poorer survival and prognostic status. In contrast, combination of BMI and smoking history did not have any correlation with clinic outcome of the lung cancer patients.
Conclusion: The results taken together indicate that BMI is associated with stage, overall survival, and disease-free survival of ovarian cancer patients and overweight/obese ovarian cancer patients at advanced stage had the worst survival and prognostic status. This is the first report providing initial evidence for an association of adiposity with hormone-related ovarian cancer in Taiwan.

REFERENCE
1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 288(14), 1723-7. 2002
2. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med. 160(7), 898-904. 2000
3. IARC. IARC Handbooks of Cancer Prevention. Weight Control and Physical Activity. International Agency for Research on Cancer: Lyon. 2002
4. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 4(8), 579-91. 2004
5. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev. 14(1), 98-107. 2005
6. WHO Expert Committee. Physical Status: the Use and Interpretation of Anthropometry. WHO Technical Report Series 854. 1995
7. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N. Engl. J. Med. 348, 1625–1638. 2003
8. Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y; Canadian Cancer Registries Epidemiology Research Group. Association of obesity and cancer risk in Canada. Am J Epidemiol. 159(3), 259-68. 2004
9. Dickson RB, Stancel GM. Estrogen receptor-mediated processes in normal and cancer cells. J. Natl Cancer Inst. Monogr. 27, 135–145. 2000
10. Flototto T, Djahansouzi S, Glaser M, Hanstein B, Niederacher D, Brumm C, Beckmann MW. Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer. Horm. Metab. Res. 33, 451–457. 2001
11. Key TJ, Pike MC. The dose-effect relationship between ‘unopposed’ estrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer. Br. J. Cancer. 57, 205–212. 1988.
12. Carmichael AR, Bates T. Obesity and breast cancer: a review of the literature. Breast. 13(2), 85-92. 2004
13. Tarone RE, Chu KC. Age-period-cohort analyses of breast-, ovarian-, endometrial-, and cervical-cancer mortality rate for Caucasian women in the USA. J Epidemiol Biostat. 5, 221–231. 2000
14. Ries LAG, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM, Vernon SW, Cronin K, Edwards BK. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 88, 2398–2424. 2000
15. Howe HL, Wingo PA, Thun MJ, Ries LAG, Rosenberg H, Edwards BK. Annual report to the nation on the status of cancer, 1973-1998, featuring cancers with recent increasing trends. J Natl Cancer Inst. 93, 824–842. 2001
16. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in cancer incidence and mortality. IARC Sci Publ. 121, 1–806. 1993
17. Goodman MT, Howe HL. Descriptive Epidemiology of Ovarian Cancer in the United States, 1992–1997. Cancer. 97(10), 2615-2629. 2003
18. Percy C, Van Holten V, Muir C. International classification of disease for oncology, 2nd edition. Geneva: World Health Organization, 1990
19. Harlow BL, Cramer DW, Bell DA, Welch WR. Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol. 80,19–26. 1992
20. Purdie DM, Bain CJ, Webb PM, Whiteman DC, Pirozzo S, Green AC. Body size and ovarian cancer: case-control study and systematic review (Australia). Cancer Causes Control. 12(9), 855-63. 2001
21. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. Version 1.0 IARC CancerBase Lyon: IARCPress; No.5. 2001.
22. Engeland A, Tretli S, Bjorge T. Height, body mass index, and ovarian cancer: a follow-up of 1.1 million Norwegian women. J Natl Cancer Inst. 95(16), 1244-8. 2003
23. Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 11(9), 822-8. 2002
24. Zhang M, Xie X, Lee AH, Binns CW, Holman CD. Body mass index in relation to ovarian cancer survival. Cancer Epidemiol Biomarkers Prev. 14(5), 1307-10. 2005
25. Health Statistics, Department of Health, Taiwan, 2000.
26. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 83, 18-29. 1999
27. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol. 23(14), 3175-85. 2005
28. Roemer R, Adrianza M, El Bedly H, Daube MM, de Givry U, Mackay J, Omar S, Ramstrom LM. Legislation to control smoking: a round table. Int Dig Health Legis. 37(3), 447- 474. l986
29. American Joint Committee on Cancer (AJCC). Lung. In: Beahrs OH, Henson DE, Hutter RVP, editors. Manual for staging of cancer, 4th ed. Philadelphia: JB Lippincott, 120. 1992
30. International Union Against Cancer (UICC). Lung tumours (ICDO-162). In: Sobin LH, Wittekind CH, editors. TNM Classification of malignant tumours, 5th ed. New York: Wiley- Liss, 1997.
31. American Thoracic Society/European Respiratory Society. Pre- treatment evaluation of non-small cell lung cancer. Am J Respir Crit Care Med. 156, 320-32. 1997
32. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J. 311, 899-909. 1995
33. Richards MA, Stockton D, Babb P, Coleman MP. How many deaths have been avoided through improvements in cancer/survival? Br Med J. 320, 8958. 2000
34. Beadsmoore CJ, Screaton NJ. Classification, staging and prognosis of lung cancer. Eur J Radio. 45, 8-17. 2003
35. Goodman MT, Wilkens LR. Relation of body size and the risk of lung cancer. Nutr Cancer. 20(2), 179-86. 1993
36. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N. Engl. J. Med. 348, 1625–1638. 2003
37. Eichholzer M, Bernasconi F, Jordan P, Stahelin HB. Body mass index and the risk of male cancer mortality of various sites: 17-year follow-up of the Basel cohort study. Swiss Med Wkly. 135(1-2), 27-33. 2005
38. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol. 101(5 Pt 1), 885-91. 2003
39. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 122(3), 1037-57. 2002
40. Pan WH, Flegal KM, Chang HY, Yeh WT, Yeh CJ, Lee WC. Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. Am J Clin Nutr. 79(1), 31-9. 2004
41. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 8(6), 541-52. 2003
42. Cancer registry annual report republic of china, 1995
43. Alam N, Shepherd FA, Winton T, Graham B, Johnson D, Livingston R, Rigas J, Whitehead M, Ding K, Seymour L. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer. 47(3), 385-94. 2005
44. Sardari Nia P, Weyler J, Colpaert C, Vermeulen P, Van Marck E, Van Schil P. Prognostic value of smoking status in operated non-small cell lung cancer. Lung Cancer. 47(3), 351-9. 2005
45. Yoshino I, Baba H, Fukuyama S, Kameyama T, Shikada Y, Tomiyasu M, Suemitsu R. A time trend of profile and surgical results in 1123 patients with non-small cell lung cancer. Surgery. 131(1 Suppl), S242-8. 2002
46. Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest. 127(3), 768-77. 2005
47. Minami H, Yoshimura M, Matsuoka H, Toshihiko S, Tsubota N. Lung cancer treated surgically in patients <50 years of age. Chest. 120(1), 32-6. 2001
48. Myrdal G, Lambe M, Gustafsson G, Nilsson K, Stahle E. Survival in primary lung cancer potentially cured by operation: influence of tumor stage and clinical characteristics. Ann Thorac Surg. 75(2), 356-63. 2003
49. Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol. 97(2), 519-23. 2005
50. Goodman MT, Howe HL. Descriptive epidemiology of ovarian cancer in the United States, 1992-1997. Cancer. 97(10 Suppl), 2615-30. 2003
51. Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J,
Kimmig R, Rehbock J, Holzel D. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer. 38(18), 2435-45. 2002
52. Yen ML, Yen BL, Bai CH, Lin RS. Risk factors for ovarian cancer in Taiwan: a case- control study in a low-incidence population. Gynecol Oncol. 89(2), 318-24. 2003
53. Aljada IS, Ramnath N, Donohue K, Harvey S, Brooks JJ, Wiseman SM, Khoury T, Loewen G, Slocum HK, Anderson TM, Bepler G, Tan D. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J Clin Oncol. 22(16), 3218-29. 2004
54. Fathalla MF. Factors in the causation and incidence of ovarian cancer. Obstet Gynecol Surv. 27,751–68. 1972